NeuroOne Medical Technologies (NASDAQ:NMTC) Releases Earnings Results, Beats Expectations By $0.30 EPS

NeuroOne Medical Technologies (NASDAQ:NMTC) posted its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.30, FiscalAI reports. The firm had revenue of $1.97 million for the quarter, compared to analyst estimates of $2.55 million. NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

• Third-quarter product revenue rose 16% year over year to $2.0 million, while product orders increased 43% to $2.7 million. Gross margin also expanded to 59.9% from 53.9%, driven by a favorable product mix.
• Manufacturing constraints left a $1.7 million backlog and caused management to lower expected fiscal 2026 recognized revenue to $9.2 million-$10.5 million, despite approximately $11.2 million in expected orders. A second, larger manufacturing site is targeted for early 2027.
• NeuroOne received ISO 13485 certification, enabling international commercialization of its OneRF Brain Ablation, OneRF Trigeminal Nerve Ablation, and Evo diagnostic product lines. The company plans to work with Zimmer Biomet and independent distributors to enter selected markets.
• The company reported progress across its pipeline, including clinical support for OneRF in patients with existing neuromodulation implants, expansion of trigeminal nerve ablation distribution, and preclinical collaborations for the StereoCED drug-delivery platform. StereoCED is expected to be ready for investigational human studies by the end of September, while the BVNA back-pain system is targeted for a 510(k) submission in the second half of calendar 2027.
• Cash and equivalents declined to $2.0 million as of June 30 from $6.6 million at fiscal year-end, while the quarterly net loss widened to $2.0 million from $1.5 million. The company raised $0.4 million during the quarter and another $1.0 million after quarter-end through its ATM program, indicating continued reliance on equity financing.

NeuroOne Medical Technologies Price Performance

Shares of NeuroOne Medical Technologies stock traded up $0.31 on Thursday, hitting $1.83. 296,705 shares of the company’s stock traded hands, compared to its average volume of 52,849. NeuroOne Medical Technologies has a one year low of $1.42 and a one year high of $6.96. The company has a fifty day moving average of $2.57 and a two-hundred day moving average of $3.80. The company has a market capitalization of $15.92 million, a price-to-earnings ratio of -2.15 and a beta of 0.61.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Weiss Ratings raised shares of NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH increased their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NeuroOne Medical Technologies has an average rating of “Hold” and an average target price of $11.67.

Insider Activity

In related news, Director Mark Christianson sold 10,000 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the sale, the director directly owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. This represents a 32.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 11.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NMTC. Goldman Sachs Group Inc. bought a new stake in NeuroOne Medical Technologies in the first quarter worth about $84,000. XTX Topco Ltd bought a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter worth approximately $51,000. Vanguard Group Inc. lifted its stake in NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after purchasing an additional 375,639 shares during the last quarter. Virtu Financial LLC bought a new position in NeuroOne Medical Technologies during the third quarter valued at $88,000. Finally, Susquehanna International Group LLP purchased a new stake in NeuroOne Medical Technologies in the third quarter worth $47,000. Institutional investors own 16.07% of the company’s stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.